Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Document › Details

Albumedix Ltd.. (6/1/20). "Press Release: Albumedix Announces Appointment of Gregor Kawaletz as Chief Commercial Officer".

Organisations Organisation Albumedix Ltd.
  Group Albumedix (Group)
  Organisation 2 IDT Biologika GmbH
  Group Klocke (Group)
Products Product recombinant human albumin (rAlb)
  Product 2 biopharmaceutical
Persons Person Kawaletz, Gregor (Albumedix 202006– CCO before IDT Biologika + Next Pharma + Catalent Pharma Solutions)
  Person 2 Møller, Jonas Skjødt (Albumedix 202007– CEO before COO since 2017)
     


Appointment strengthens company’s position in advanced therapies


Albumedix Ltd. (‘Albumedix’), the world leader in recombinant human albumin (rAlb), announced today the strengthening of its Executive Leadership with the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.

Gregor brings more than 25 years’ experience within the life science sector and extensive operational experience from previous commercial roles at Catalent Pharma Solutions and Next Pharma, and most recently as Chief Commercial Officer at IDT-Biologika GmbH. His clear focus on commercial execution and building strong client relationships has driven consistent growth across several segments in the advanced therapy space throughout his career.

Speaking on the new appointment to the Executive team, Jonas Skjødt Møller, Chief Executive Officer, Albumedix, commented, “We are thrilled to welcome Gregor to Albumedix. He is an extremely accomplished executive, displaying the right balance between being an effective negotiator and a people-focused leader, with an impressive commercial track record. We see a sustainable growth opportunity for the business, driven by our strong market momentum enabling stable and scalable therapeutics to reach patients globally. With Gregor joining our team, we are well-placed to drive further growth together with our customers and take Albumedix to the next level, both in terms of market reach, patient impact and value creation.”

At Albumedix, Gregor’s focus will be on strengthening the company's position as partner of choice within advanced therapies, and on driving revenue growth and business acceleration across key market segments. He will be responsible for establishing strategic partnerships in new markets, expanding and progressing Albumedix’ customer portfolio, and extending the global footprint of the company. Albumedix are actively working on expanding capacity of their manufacturing site to accommodate this growing demand in advanced therapies and biopharmaceuticals. Together with Jonas and the rest of the Executive Leadership at Albumedix, Gregor will support the next wave of expansion and commercial reach.

Commenting on his new appointment, Gregor said, “I am delighted to join the Albumedix ‘family’; a passionate and like-minded group of talented individuals all striving toward a common goal to address critical challenges with biologics and vaccines through strategic partnering and pioneering solutions. Albumedix offers a unique, and highly sought-after product range that has the potential to dramatically transform the development of complex drugs, such as cellular therapies, next-generation viral vaccines and gene therapies. We have a lot to be proud of, and with the market growing rapidly, Albumedix has so much to offer. There really is so much to explore and I am in the right place at the right time to maximize this exciting opportunity.”

For more information about Albumedix recombinant human albumin products, click here.

   
Record changed: 2020-06-08

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Albumedix (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top